查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2016948

靜脈通路裝置市場：按類型、年齡層、最終用戶和應用分類－2026-2032年全球市場預測

Vascular Access Device Market by Type, Age Group, End User, Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，靜脈通路裝置市值將達到 91.5 億美元，到 2026 年將成長至 96.9 億美元，到 2032 年將達到 138.4 億美元，複合年成長率為 6.09%。

主要市場統計數據
基準年 2025 91.5億美元
預計年份：2026年 96.9億美元
預測年份 2032 138.4億美元
複合年成長率 (%) 6.09%

策略部署概述了正在重塑靜脈通路裝置。

靜脈通路裝置是現代醫療介入措施的基礎，涵蓋從常規靜脈輸液到複雜的化療方案和長期居家輸液等許多面向。隨著臨床團隊將感染預防、病患舒適度和手術效率置於優先地位，裝置的選擇越來越反映出材料科學、人體工學和醫療服務物流的交叉融合。導管材料和塗層技術的進步，以及手術流程的標準化和血管通路團隊模式的建立，正在重塑臨床路徑和治療效果。

對技術創新、護理環境轉變和採購系統演變的分析，這些因素同時重新定義了競爭優勢和臨床結果。

由於技術創新、醫療環境的轉變以及臨床實踐的不斷發展，血管通路領域正經歷變革性的變革。抗菌和抗血栓塗層的創新，以及先進的聚合物化學技術，正在提高導管的耐用性並降低感染風險。同時，設計上的改進增強了導管的插入便利性和固定可靠性。此外，與設備相容的感測器和輸液泵的數位化整合，正在豐富術後監測，並為臨床醫生提供可用的數據。

對近期價格調整如何重組整個血管通路供應鏈的採購、製造地和籌資策略進行詳細評估。

關稅調整帶來的政策環境變化，正促使靜脈通路裝置產業對整個供應鏈和籌資策略進行策略性重新評估。製造商和醫療採購商正在調整採購慣例，以適應不斷變化的投入成本和貿易趨勢。這加速了供應商多元化、探索近岸外包機會以及談判長期供應商合約的進程，從而保護臨床營運免受短期價格波動的影響。

透過對設備類型、年齡層、最終用戶和臨床應用進行綜合細分分析，可以發現有針對性的產品和服務機會。

透過分析細分市場層面的趨勢，我們揭示了臨床需求、醫療環境和產品表現如何相互作用，從而驅動不同類型器材和使用者群體的採用模式。根據器械類型，我們將市場細分為中央靜脈導管和周邊靜脈通路裝置，其中周邊靜脈通路裝置進一步細分為長周邊靜脈導管和短周邊靜脈導管。這種區分至關重要，因為中心靜脈裝置是高容量或長期治療的必需品，而周邊裝置則最適合常規和短期輸液。按年齡層別分類，我們分析了成人、老年人和兒童群體的市場，強調了根據生理差異和照護環境，在尺寸、插入技術和安全功能方面進行個別化設計的必要性。

區域分析比較美洲、歐洲、中東和非洲以及亞太市場的臨床引入模式、監管細微差別和商業性需求。

無論具體司法管轄區如何，區域趨勢都在影響著技術採納的速度和商業性機會的結構。在美洲，整合的臨床證據和報銷方案的協調一致往往是優先考慮的因素，醫療機構對能夠顯著降低醫院感染併發症的設備有著強烈的需求。歐洲和中東及非洲地區的情況則較為複雜，監管協調的努力與不同的採購模式和居家醫療基礎設施水平並存，導致一些地區快速採納新技術，而另一些地區則仍然對價格敏感。在亞太地區，既有成熟的大都會圈採用尖端導管技術，也有大規模新興市場，在這些市場中，規模、成本效益和供應穩定性正在影響醫療服務提供者的選擇。

對競爭策略、夥伴關係模式和創新路徑的評估，決定哪些公司在臨床引入和業務擴張方面處於主導。

靜脈通路裝置領域的競爭動態呈現出成熟醫療技術公司與敏捷創新者並駕齊驅的態勢，後者不斷將特種材料、塗層和數位整合技術推向市場。主要企業專注於涵蓋中心靜脈和周邊靜脈通路解決方案的廣泛產品系列，同時投資於臨床試驗、上市後監測和培訓項目，以提升其對醫院和居家照護機構的價值提案。同時，小規模的專業公司和Start-Ups正在推出差異化技術，例如新一代抗菌處理、整合感測器的裝置和微創插入系統，以應對特定的臨床挑戰。

為經營團隊提供實用建議，以整合產品開發、臨床證據、供應彈性和行銷策略，從而確保永續的競爭優勢。

行業領導企業應採取果斷行動，使產品開發、商業策略和業務永續營運與臨床醫生和醫療保健專業人員不斷變化的需求保持一致。首先，應優先考慮產品組合細分，使設備與最終用戶需求相符。考慮插入流程、維護預期和培訓需求，並為醫院、門診中心和居家醫療開發不同的提案。其次，應投資於臨床證據和衛生經濟學分析，以量化安全性和營運效益，從而在處方集中佔據更有利的地位，並提高與支付方的合作度。

本報告對用於得出報告結論的主要和次要調查方法、相關人員訪談和資料三角驗證技術進行了透明的解釋。

本分析的調查方法結合了主要相關人員的直接參與、全面的二手資料研究和結構化的整合，從而確保了研究結果的可靠性和可操作性。主要資料來源包括對臨床醫生、血管通路護理師、採購經理和器械開發人員的訪談，旨在了解臨床工作流程、未滿足的需求和採購標準等方面的實際觀點。這些定性研究結果與監管文件、臨床文獻、器械標籤和專業協會發布的公共指南等二級資訊來源資料進行了交叉比對，以檢驗性能聲明和安全性方面的考慮。

簡潔、綜合的結論，概括了臨床創新、供應鏈韌性和服務主導商業化的策略挑戰。

現有證據清晰地表明，臨床需求、醫療服務地點的轉變以及供應鏈趨勢正在重塑靜脈通路裝置的市場結構。注重安全性、易用性和與分散式醫療模式相容性的器材創新，將受到醫院、門診中心和居家醫療機構的青睞。同時，商業性成功取決於能否將卓越的產品與臨床證據、全面的培訓以及可靠的供應鏈結合。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：靜脈通路裝置市場：依類型分類

  • 中央靜脈導管
  • 靜脈通路裝置
    • 長周邊靜脈導管
    • 短周邊靜脈導管

第9章：靜脈通路裝置市場：依年齡層別分類

  • 成人版
  • 老年人
  • 兒童

第10章：靜脈通路裝置市場：依最終用戶分類

  • 門診手術中心
  • 居家醫療設施
  • 醫院和診所

第11章：靜脈通路裝置市場：依應用分類

  • 輸血
  • 診斷和檢查
  • 藥物管理
    • 靜脈注射抗生素
    • 化療

第12章：靜脈通路裝置市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：靜脈通路裝置市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章靜脈通路裝置市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國靜脈通路裝置市場

第16章：中國靜脈通路裝置市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • 3M Company
  • Access Vascular, Inc.
  • AMECATH
  • AngioDynamics, Inc.
  • Argon Medical Devices, Inc.
  • Asahi Kasei Medical Co., Ltd.
  • B. Braun Melsungen AG
  • Baxter International Inc.
  • Becton, Dickinson and Company
  • Cook Medical, Inc.
  • Edwards Lifesciences Corporation
  • Fresenius Medical Care AG & Co. KGaA
  • Fujifilm Sonosite, Inc.
  • ICU Medical, Inc.
  • Kimal PLC
  • Medical Components, Inc.
  • Medtronic PLC
  • Nipro Medical Corporation
  • Prodimed
  • Siemens Healthcare AG
  • Teleflex Incorporated
  • Terumo Corporation
  • Versago Vascular Access
  • Vygon SA
  • WL Gore & Associates, Inc
Product Code: MRR-034B50030371

The Vascular Access Device Market was valued at USD 9.15 billion in 2025 and is projected to grow to USD 9.69 billion in 2026, with a CAGR of 6.09%, reaching USD 13.84 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 9.15 billion
Estimated Year [2026] USD 9.69 billion
Forecast Year [2032] USD 13.84 billion
CAGR (%) 6.09%

A strategic introduction framing clinical drivers, material innovations, and care-delivery changes that are reshaping vascular access device adoption and use

Vascular access devices underpin a wide range of contemporary healthcare interventions, from routine intravenous therapy to complex chemotherapy regimens and extended home infusions. As clinical teams prioritize infection prevention, patient comfort, and procedural efficiency, device choice increasingly reflects the intersection of material science, human factors engineering, and care-delivery logistics. Advances in catheter materials and coatings, combined with procedural standardization and vascular access team models, are reshaping clinical pathways and care outcomes.

This introduction frames the strategic context for stakeholders across manufacturing, clinical operations, and supply chain management. Hospitals and ambulatory providers face pressure to optimize device selection not only for immediate procedural success but also for downstream metrics such as catheter-related complications, dwell time, and readmission risk. Meanwhile, the shift toward decentralized care models has elevated the importance of devices that support safe home administration and remote monitoring, requiring manufacturers to consider durability, ease of insertion, and compatibility with infusion systems.

Regulatory scrutiny and payer attention further shape product development priorities, encouraging demonstrable safety benefits and clear value propositions. Together, these clinical and commercial drivers create an environment in which incremental design improvements and integrated service offerings can translate quickly into competitive advantage when coupled with rigorous clinical evidence and pragmatic operational support.

An analysis of technological innovations, care-site migration, and procurement evolution that are jointly redefining competitive advantage and clinical outcomes

The vascular access landscape is experiencing transformative shifts driven by technological innovation, changing care settings, and evolving clinical practice. Innovations in antimicrobial and antithrombotic coatings, alongside refined polymer chemistry, are improving catheter longevity and reducing infection risks, while design refinements enhance insertion ergonomics and securement reliability. Simultaneously, digital integration such as device-compatible sensors and infusion pumps is enabling richer post-procedural monitoring and actionable data for clinicians.

Care delivery has shifted proportionally toward outpatient and home settings, prompting devices that prioritize user-friendly interfaces, simplified maintenance, and compatibility with at-home infusion protocols. This transition has been accelerated by workforce constraints in acute care and by payer incentives that support care-site optimization. Training and credentialing for vascular access teams have become central to ensuring consistent outcomes, with institutions investing in specialized teams to reduce complication rates and improve first-attempt success.

Procurement strategies are also adapting: providers increasingly favor vendors offering bundled clinical support, education, and data analytics rather than transactional product supply alone. Regulatory frameworks are evolving to emphasize post-market surveillance and real-world evidence, creating both obligations and opportunities for manufacturers to demonstrate sustained clinical value. Taken together, these shifts create a dynamic environment in which agility, clinical partnership, and evidence generation determine market success.

A detailed assessment of how recent tariff adjustments have reshaped sourcing, manufacturing footprints, and procurement strategies across the vascular access supply chain

The policy environment introduced by tariff changes has prompted a strategic reassessment across supply chains and sourcing strategies within the vascular access device sector. Manufacturers and healthcare purchasers are adapting procurement practices in response to altered input costs and shifting trade dynamics. This has accelerated efforts to diversify supplier bases, explore nearshoring opportunities, and negotiate long-term supplier agreements that insulate clinical operations from episodic price volatility.

Manufacturers have reacted by optimizing production footprints and re-evaluating material choices to manage cost pressure while preserving clinical performance. Some firms have invested in alternative polymer sources, sought efficiencies in sterilization workflows, and accelerated automation to reduce labor intensity. For providers, contracting strategies are emphasizing total cost of ownership and supplier reliability, with greater willingness to engage in value-based arrangements that balance device price against clinical outcomes and supply continuity.

Procurement teams are increasingly modeling scenario-based inventory strategies that prioritize critical SKUs and build redundancy across logistics providers. At the same time, regulatory compliance for imported medical devices demands careful attention to documentation and quality controls, adding complexity to cross-border sourcing. These cumulative effects create both headwinds and incentives for innovation, as companies that can deliver clinically differentiated devices while managing input cost exposure will be better positioned to meet provider needs in a more constrained trade environment.

Comprehensive segmentation analysis connecting device types, age cohorts, end users, and clinical applications to reveal targeted product and service opportunities

Segment-level dynamics reveal where clinical demand, care settings, and product performance intersect to drive adoption patterns across different device types and user populations. Based on Type, the market is studied across Central Venous Catheters and Peripheral Vascular Access Devices, with the Peripheral Vascular Access Devices further delineated into Long Peripheral Intravenous Catheter and Short Peripheral Intravenous Catheter; this differentiation matters because central devices remain essential for high-volume or long-term therapies while peripheral options optimize routine and short-duration infusions. Based on Age Group, the market is studied across Adult, Geriatric, and Pediatric cohorts, which highlights the need for tailored sizing, insertion techniques, and safety features to accommodate physiological differences and care environments.

Based on End User, the market is studied across Ambulatory Surgical Centers, Home Healthcare Settings, and Hospitals & Clinics, revealing distinct procurement priorities and support requirements: ambulatory providers prioritize first-attempt success and throughput, homecare emphasizes device simplicity and remote support, and hospitals balance a broad clinical portfolio with the need for durable, multi-indication devices. Based on Application, the market is studied across Blood Transfusion, Diagnostics & Testing, and Drug Administration, with Drug Administration further segmented into Antibiotic Infusion and Chemotherapy; these application niches drive device selection through differing dwell-time expectations, compatibility with infusion regimens, and risk tolerance for complications.

Across these intersecting segments, manufacturers and clinicians can identify high-value opportunities by aligning product design, training investments, and evidence-generation with the specific clinical workflows and risk profiles of each cohort. For example, pediatric device innovation focuses on minimized lumen size and atraumatic insertion, while home healthcare solutions emphasize securement systems and clear maintenance protocols that reduce the burden on non-clinical caregivers.

Regional intelligence that contrasts clinical adoption patterns, regulatory nuance, and commercial imperatives across the Americas, Europe Middle East Africa, and Asia-Pacific markets

Regional dynamics shape both the pace of technological adoption and the structure of commercial opportunity across jurisdictions. Americas markets often prioritize integrated clinical evidence and reimbursement alignment, with strong institutional demand for devices that demonstrate measurable reductions in hospital-acquired complications. Europe, Middle East & Africa display a heterogeneous landscape where regulatory harmonization efforts coexist with varied procurement models and differing levels of homecare infrastructure, creating pockets of rapid adoption alongside regions that remain price sensitive. Asia-Pacific presents a mix of mature metropolitan centers adopting cutting-edge catheter technologies and large emerging markets where scale, cost-efficiency, and supply resilience drive provider choices.

These regional distinctions imply that commercial approaches must be adapted carefully. In the Americas, investments in clinical trials and health economic dossiers can unlock hospital formulary approvals and contracted placements. In Europe, Middle East & Africa, success often depends on tailored regulatory strategies and partnerships with regional distributors that understand local procurement dynamics. In Asia-Pacific, scalable manufacturing, localized training programs, and flexible pricing that addresses both urban tertiary centers and resource-constrained facilities become central to expanding reach.

Cross-region collaboration and knowledge transfer offer opportunities to accelerate adoption of best practices. Manufacturers that build regional evidence packages and deploy adaptable service models will be better placed to capture heterogeneous demand while supporting consistent safety and quality standards across global care settings.

An evaluation of competitive strategies, partnership models, and innovation pathways that determine which firms will lead in clinical adoption and commercial expansion

Competitive dynamics within the vascular access device arena are defined by a blend of established medtech firms and nimble innovators that bring specialized materials, coatings, and digital integration to market. Leading companies concentrate on broad portfolios that span central and peripheral access solutions while investing in clinical studies, post-market surveillance, and training programs that reinforce their value propositions to hospitals and homecare providers. At the same time, smaller specialists and startups are introducing differentiated technologies such as next-generation antimicrobial treatments, sensor-enabled devices, and minimally invasive insertion systems that address specific clinical pain points.

Partnerships and collaborative models are common as firms seek to combine manufacturing scale with clinical expertise and channel access. Strategic alliances with distributors, infusion service providers, and health systems enable faster market penetration and generate the real-world evidence necessary for broader adoption. Mergers and acquisitions remain a viable route to rapidly expand product catalogs and geographic reach, but disciplined integration and continued investment in R&D are critical to realize expected synergies.

Manufacturers that succeed will balance innovation with operational excellence: they will maintain robust quality systems, ensure regulatory readiness across jurisdictions, and offer comprehensive clinical support that reduces the operational burden on purchasers. Commercially, differentiation will come from demonstrated outcomes, integrated service offerings, and the ability to deliver consistent supply under evolving trade conditions.

Actionable recommendations for executives to synchronize product development, clinical evidence, supply resilience, and go-to-market strategies for durable advantage

Industry leaders should act decisively to align product development, commercial strategy, and operational resilience with the evolving demands of clinicians and care settings. First, prioritize portfolio segmentation that matches devices to end-user needs: develop distinct propositions for hospitals, ambulatory centers, and homecare that account for insertion workflows, maintenance expectations, and training needs. Second, invest in clinical evidence and health economic analyses that quantify safety and operational benefits, enabling stronger formulary positioning and payer engagement.

Third, strengthen supply chain resilience through supplier diversification, selective nearshoring, and inventory risk management to mitigate the effects of trade shifts and tariffs. Fourth, accelerate development of features that support decentralized care, such as simplified securement systems, compatibility with portable infusion pumps, and intuitive maintenance instructions for non-clinical caregivers. Fifth, build service-oriented offerings that bundle devices with training, remote support, and data analytics to lock in longer-term partnerships and create differentiated revenue streams.

Finally, engage proactively with regulatory bodies to streamline approvals and demonstrate commitment to post-market surveillance. Embrace sustainability practices where feasible to meet rising institutional expectations and to lower lifecycle costs. By integrating these priorities into a coordinated strategy, manufacturers and providers can improve patient outcomes while capturing sustainable commercial value.

A transparent description of primary and secondary research methods, stakeholder interviews, and data triangulation techniques used to generate the report's conclusions

The research methodology underpinning this analysis combines primary stakeholder engagement with comprehensive secondary review and structured synthesis to ensure robust, actionable findings. Primary inputs included interviews with clinicians, vascular access nurses, procurement leaders, and device developers to capture frontline perspectives on clinical workflows, unmet needs, and purchasing criteria. These qualitative insights were triangulated with secondary sources including regulatory filings, clinical literature, device labeling, and publicly available guidance from professional societies to validate performance claims and safety considerations.

Supply chain and commercial assessments relied on supplier mapping, patent landscape review, and analysis of distribution models to identify sources of resilience and potential bottlenecks. The approach emphasized cross-validation between clinical feedback and operational data to surface pragmatic recommendations. Where appropriate, case studies were used to illustrate successful deployment models and to extract transferable lessons on training, change management, and evidence generation.

Throughout the process, findings were subjected to iterative expert review and quality assurance to minimize bias and ensure clarity. Limitations include the dynamic nature of regulatory policy and trade environments, which may evolve after data collection; therefore, recommendations emphasize adaptive strategies rather than fixed prescriptions.

A concise synthesizing conclusion that distills strategic imperatives across clinical innovation, supply resilience, and service-driven commercialization

The cumulative evidence paints a clear picture: clinical needs, care-site migration, and supply-chain dynamics are converging to reshape the vascular access device landscape. Device innovation that focuses on safety, ease of use, and compatibility with decentralized care models will find growing demand among hospitals, ambulatory centers, and home healthcare providers. At the same time, commercial success will hinge on the ability to pair product excellence with clinical evidence, robust training, and reliable supply arrangements.

Tariff-induced trade adjustments and regional policy variation add complexity but also create incentives for operational optimization and strategic partnerships. Organizations that proactively invest in differentiated device features, service bundles, and regulatory readiness can reduce procurement friction and accelerate adoption across varied market segments. Clinicians and procurement leaders alike will reward solutions that demonstrably lower complication rates, simplify workflows, and support safe care outside the traditional inpatient setting.

In conclusion, the sector favors companies that combine technological sophistication with practical support models and resilient operations. Those that integrate clinical validation, supply-chain foresight, and targeted regional approaches will be best positioned to capture value while improving patient outcomes across care settings.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Vascular Access Device Market, by Type

  • 8.1. Central Venous Catheters
  • 8.2. Peripheral Vascular Access Devices
    • 8.2.1. Long Peripheral Intravenous Catheter
    • 8.2.2. Short Peripheral Intravenous Catheter

9. Vascular Access Device Market, by Age Group

  • 9.1. Adult
  • 9.2. Geriatric
  • 9.3. Pediatric

10. Vascular Access Device Market, by End User

  • 10.1. Ambulatory Surgical Centers
  • 10.2. Home Healthcare Settings
  • 10.3. Hospitals & Clinics

11. Vascular Access Device Market, by Application

  • 11.1. Blood Transfusion
  • 11.2. Diagnostics & Testing
  • 11.3. Drug Administration
    • 11.3.1. Antibiotic Infusion
    • 11.3.2. Chemotherapy

12. Vascular Access Device Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Vascular Access Device Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Vascular Access Device Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Vascular Access Device Market

16. China Vascular Access Device Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. 3M Company
  • 17.6. Access Vascular, Inc.
  • 17.7. AMECATH
  • 17.8. AngioDynamics, Inc.
  • 17.9. Argon Medical Devices, Inc.
  • 17.10. Asahi Kasei Medical Co., Ltd.
  • 17.11. B. Braun Melsungen AG
  • 17.12. Baxter International Inc.
  • 17.13. Becton, Dickinson and Company
  • 17.14. Cook Medical, Inc.
  • 17.15. Edwards Lifesciences Corporation
  • 17.16. Fresenius Medical Care AG & Co. KGaA
  • 17.17. Fujifilm Sonosite, Inc.
  • 17.18. ICU Medical, Inc.
  • 17.19. Kimal PLC
  • 17.20. Medical Components, Inc.
  • 17.21. Medtronic PLC
  • 17.22. Nipro Medical Corporation
  • 17.23. Prodimed
  • 17.24. Siemens Healthcare AG
  • 17.25. Teleflex Incorporated
  • 17.26. Terumo Corporation
  • 17.27. Versago Vascular Access
  • 17.28. Vygon SA
  • 17.29. W. L. Gore & Associates, Inc

LIST OF FIGURES

  • FIGURE 1. GLOBAL VASCULAR ACCESS DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL VASCULAR ACCESS DEVICE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL VASCULAR ACCESS DEVICE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL VASCULAR ACCESS DEVICE MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL VASCULAR ACCESS DEVICE MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL VASCULAR ACCESS DEVICE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL VASCULAR ACCESS DEVICE MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL VASCULAR ACCESS DEVICE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL VASCULAR ACCESS DEVICE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL VASCULAR ACCESS DEVICE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES VASCULAR ACCESS DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA VASCULAR ACCESS DEVICE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL VASCULAR ACCESS DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL VASCULAR ACCESS DEVICE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL VASCULAR ACCESS DEVICE MARKET SIZE, BY CENTRAL VENOUS CATHETERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL VASCULAR ACCESS DEVICE MARKET SIZE, BY CENTRAL VENOUS CATHETERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL VASCULAR ACCESS DEVICE MARKET SIZE, BY CENTRAL VENOUS CATHETERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL VASCULAR ACCESS DEVICE MARKET SIZE, BY PERIPHERAL VASCULAR ACCESS DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL VASCULAR ACCESS DEVICE MARKET SIZE, BY PERIPHERAL VASCULAR ACCESS DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL VASCULAR ACCESS DEVICE MARKET SIZE, BY PERIPHERAL VASCULAR ACCESS DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL VASCULAR ACCESS DEVICE MARKET SIZE, BY PERIPHERAL VASCULAR ACCESS DEVICES, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL VASCULAR ACCESS DEVICE MARKET SIZE, BY LONG PERIPHERAL INTRAVENOUS CATHETER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL VASCULAR ACCESS DEVICE MARKET SIZE, BY LONG PERIPHERAL INTRAVENOUS CATHETER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL VASCULAR ACCESS DEVICE MARKET SIZE, BY LONG PERIPHERAL INTRAVENOUS CATHETER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL VASCULAR ACCESS DEVICE MARKET SIZE, BY SHORT PERIPHERAL INTRAVENOUS CATHETER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL VASCULAR ACCESS DEVICE MARKET SIZE, BY SHORT PERIPHERAL INTRAVENOUS CATHETER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL VASCULAR ACCESS DEVICE MARKET SIZE, BY SHORT PERIPHERAL INTRAVENOUS CATHETER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL VASCULAR ACCESS DEVICE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL VASCULAR ACCESS DEVICE MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL VASCULAR ACCESS DEVICE MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL VASCULAR ACCESS DEVICE MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL VASCULAR ACCESS DEVICE MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL VASCULAR ACCESS DEVICE MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL VASCULAR ACCESS DEVICE MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL VASCULAR ACCESS DEVICE MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL VASCULAR ACCESS DEVICE MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL VASCULAR ACCESS DEVICE MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL VASCULAR ACCESS DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL VASCULAR ACCESS DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL VASCULAR ACCESS DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL VASCULAR ACCESS DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL VASCULAR ACCESS DEVICE MARKET SIZE, BY HOME HEALTHCARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL VASCULAR ACCESS DEVICE MARKET SIZE, BY HOME HEALTHCARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL VASCULAR ACCESS DEVICE MARKET SIZE, BY HOME HEALTHCARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL VASCULAR ACCESS DEVICE MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL VASCULAR ACCESS DEVICE MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL VASCULAR ACCESS DEVICE MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL VASCULAR ACCESS DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL VASCULAR ACCESS DEVICE MARKET SIZE, BY BLOOD TRANSFUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL VASCULAR ACCESS DEVICE MARKET SIZE, BY BLOOD TRANSFUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL VASCULAR ACCESS DEVICE MARKET SIZE, BY BLOOD TRANSFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL VASCULAR ACCESS DEVICE MARKET SIZE, BY DIAGNOSTICS & TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL VASCULAR ACCESS DEVICE MARKET SIZE, BY DIAGNOSTICS & TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL VASCULAR ACCESS DEVICE MARKET SIZE, BY DIAGNOSTICS & TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL VASCULAR ACCESS DEVICE MARKET SIZE, BY DRUG ADMINISTRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL VASCULAR ACCESS DEVICE MARKET SIZE, BY DRUG ADMINISTRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL VASCULAR ACCESS DEVICE MARKET SIZE, BY DRUG ADMINISTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL VASCULAR ACCESS DEVICE MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL VASCULAR ACCESS DEVICE MARKET SIZE, BY ANTIBIOTIC INFUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL VASCULAR ACCESS DEVICE MARKET SIZE, BY ANTIBIOTIC INFUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL VASCULAR ACCESS DEVICE MARKET SIZE, BY ANTIBIOTIC INFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL VASCULAR ACCESS DEVICE MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL VASCULAR ACCESS DEVICE MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL VASCULAR ACCESS DEVICE MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL VASCULAR ACCESS DEVICE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS VASCULAR ACCESS DEVICE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS VASCULAR ACCESS DEVICE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS VASCULAR ACCESS DEVICE MARKET SIZE, BY PERIPHERAL VASCULAR ACCESS DEVICES, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS VASCULAR ACCESS DEVICE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. AMERICAS VASCULAR ACCESS DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 59. AMERICAS VASCULAR ACCESS DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS VASCULAR ACCESS DEVICE MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA VASCULAR ACCESS DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. NORTH AMERICA VASCULAR ACCESS DEVICE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA VASCULAR ACCESS DEVICE MARKET SIZE, BY PERIPHERAL VASCULAR ACCESS DEVICES, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA VASCULAR ACCESS DEVICE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA VASCULAR ACCESS DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA VASCULAR ACCESS DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA VASCULAR ACCESS DEVICE MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA VASCULAR ACCESS DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA VASCULAR ACCESS DEVICE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA VASCULAR ACCESS DEVICE MARKET SIZE, BY PERIPHERAL VASCULAR ACCESS DEVICES, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA VASCULAR ACCESS DEVICE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA VASCULAR ACCESS DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA VASCULAR ACCESS DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA VASCULAR ACCESS DEVICE MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA VASCULAR ACCESS DEVICE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA VASCULAR ACCESS DEVICE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA VASCULAR ACCESS DEVICE MARKET SIZE, BY PERIPHERAL VASCULAR ACCESS DEVICES, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA VASCULAR ACCESS DEVICE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA VASCULAR ACCESS DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA VASCULAR ACCESS DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA VASCULAR ACCESS DEVICE MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE VASCULAR ACCESS DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE VASCULAR ACCESS DEVICE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE VASCULAR ACCESS DEVICE MARKET SIZE, BY PERIPHERAL VASCULAR ACCESS DEVICES, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE VASCULAR ACCESS DEVICE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE VASCULAR ACCESS DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE VASCULAR ACCESS DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE VASCULAR ACCESS DEVICE MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST VASCULAR ACCESS DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST VASCULAR ACCESS DEVICE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST VASCULAR ACCESS DEVICE MARKET SIZE, BY PERIPHERAL VASCULAR ACCESS DEVICES, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST VASCULAR ACCESS DEVICE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. MIDDLE EAST VASCULAR ACCESS DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. MIDDLE EAST VASCULAR ACCESS DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST VASCULAR ACCESS DEVICE MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA VASCULAR ACCESS DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA VASCULAR ACCESS DEVICE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. AFRICA VASCULAR ACCESS DEVICE MARKET SIZE, BY PERIPHERAL VASCULAR ACCESS DEVICES, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA VASCULAR ACCESS DEVICE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. AFRICA VASCULAR ACCESS DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. AFRICA VASCULAR ACCESS DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 102. AFRICA VASCULAR ACCESS DEVICE MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC VASCULAR ACCESS DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC VASCULAR ACCESS DEVICE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC VASCULAR ACCESS DEVICE MARKET SIZE, BY PERIPHERAL VASCULAR ACCESS DEVICES, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC VASCULAR ACCESS DEVICE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC VASCULAR ACCESS DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC VASCULAR ACCESS DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC VASCULAR ACCESS DEVICE MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL VASCULAR ACCESS DEVICE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN VASCULAR ACCESS DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. ASEAN VASCULAR ACCESS DEVICE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. ASEAN VASCULAR ACCESS DEVICE MARKET SIZE, BY PERIPHERAL VASCULAR ACCESS DEVICES, 2018-2032 (USD MILLION)
  • TABLE 114. ASEAN VASCULAR ACCESS DEVICE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. ASEAN VASCULAR ACCESS DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. ASEAN VASCULAR ACCESS DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 117. ASEAN VASCULAR ACCESS DEVICE MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 118. GCC VASCULAR ACCESS DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GCC VASCULAR ACCESS DEVICE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. GCC VASCULAR ACCESS DEVICE MARKET SIZE, BY PERIPHERAL VASCULAR ACCESS DEVICES, 2018-2032 (USD MILLION)
  • TABLE 121. GCC VASCULAR ACCESS DEVICE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GCC VASCULAR ACCESS DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. GCC VASCULAR ACCESS DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 124. GCC VASCULAR ACCESS DEVICE MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION VASCULAR ACCESS DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPEAN UNION VASCULAR ACCESS DEVICE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPEAN UNION VASCULAR ACCESS DEVICE MARKET SIZE, BY PERIPHERAL VASCULAR ACCESS DEVICES, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPEAN UNION VASCULAR ACCESS DEVICE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPEAN UNION VASCULAR ACCESS DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPEAN UNION VASCULAR ACCESS DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPEAN UNION VASCULAR ACCESS DEVICE MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 132. BRICS VASCULAR ACCESS DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. BRICS VASCULAR ACCESS DEVICE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. BRICS VASCULAR ACCESS DEVICE MARKET SIZE, BY PERIPHERAL VASCULAR ACCESS DEVICES, 2018-2032 (USD MILLION)
  • TABLE 135. BRICS VASCULAR ACCESS DEVICE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. BRICS VASCULAR ACCESS DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. BRICS VASCULAR ACCESS DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 138. BRICS VASCULAR ACCESS DEVICE MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 139. G7 VASCULAR ACCESS DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. G7 VASCULAR ACCESS DEVICE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. G7 VASCULAR ACCESS DEVICE MARKET SIZE, BY PERIPHERAL VASCULAR ACCESS DEVICES, 2018-2032 (USD MILLION)
  • TABLE 142. G7 VASCULAR ACCESS DEVICE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. G7 VASCULAR ACCESS DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. G7 VASCULAR ACCESS DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 145. G7 VASCULAR ACCESS DEVICE MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 146. NATO VASCULAR ACCESS DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. NATO VASCULAR ACCESS DEVICE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. NATO VASCULAR ACCESS DEVICE MARKET SIZE, BY PERIPHERAL VASCULAR ACCESS DEVICES, 2018-2032 (USD MILLION)
  • TABLE 149. NATO VASCULAR ACCESS DEVICE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. NATO VASCULAR ACCESS DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. NATO VASCULAR ACCESS DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 152. NATO VASCULAR ACCESS DEVICE MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL VASCULAR ACCESS DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. UNITED STATES VASCULAR ACCESS DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 155. UNITED STATES VASCULAR ACCESS DEVICE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. UNITED STATES VASCULAR ACCESS DEVICE MARKET SIZE, BY PERIPHERAL VASCULAR ACCESS DEVICES, 2018-2032 (USD MILLION)
  • TABLE 157. UNITED STATES VASCULAR ACCESS DEVICE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. UNITED STATES VASCULAR ACCESS DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. UNITED STATES VASCULAR ACCESS DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 160. UNITED STATES VASCULAR ACCESS DEVICE MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 161. CHINA VASCULAR ACCESS DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 162. CHINA VASCULAR ACCESS DEVICE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. CHINA VASCULAR ACCESS DEVICE MARKET SIZE, BY PERIPHERAL VASCULAR ACCESS DEVICES, 2018-2032 (USD MILLION)
  • TABLE 164. CHINA VASCULAR ACCESS DEVICE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. CHINA VASCULAR ACCESS DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 166. CHINA VASCULAR ACCESS DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 167. CHINA VASCULAR ACCESS DEVICE MARKET SIZE, BY DRUG ADMINISTRATION, 2018-2032 (USD MILLION)